CNMD Stock Analysis: Buy, Sell, or Hold?
CNMD - CONMED Corporation
$38.48
1.79 (4.88%)
▲
5d:
+13.75%
30d:
+4.28%
90d:
+4.2%
HOLD
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Jul 29, 2026
15d
Get Alerted When CNMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: CNMD is 7.1% above its trading range ($35.94). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: CNMD is 7.1% above its trading range ($35.94). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$53.10
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$32.97
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CNMD is currently trading at $38.48, which is considered extended relative to its 30-day fair value range of $33.07 to $35.94. The stock's valuation (Forward PE: 8.1) is in line with its historical norms (8.1). Remarkably, the market is currently pricing in an annual earnings decline of 0.1% over the next few years. This pessimistic expectation contrasts with the company's recent 136.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CNMD is in a strong downtrend. The price is approaching resistance at $38.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: CNMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CNMD is in a strong downtrend. The price is approaching resistance at $38.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: CNMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$33.07 -
$35.94
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range (+7.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- NEUTRAL: Near Wall St target ($39.60)
Trading Range Analysis
30-Day Trading Range
$33.07 -
$35.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$32.10
Resistance Level
$38.73
Current Trend
Strong Downtrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.07
Wall Street Target
$39.60
(+2.9%)
Revenue Growth (YoY)
-1.3%
Earnings Growth (YoY)
136.8%
Profit Margin
4.0%
Valuation Discount vs History
-0.1% cheaper
PE vs Historical
8.1 vs 8.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.1%
(market-implied from PE analysis)
1-Year Target
$38.44
(0%)
2-Year Target
$38.40
(0%)
3-Year Target
$38.36
(0%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
$38.49
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.2%)
$135.15
(+251%)
Base:
(SPY PE: 8.1, Growth: 9.2%)
$50.10
(+30%)
Bear:
(PE: 6.9, Growth: 9.2%)
$42.58
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 20.73 | Current EPS (TTM): $1.77
Bull Case
$80.72
(+110%)
Analyst growth 100.0%, PE expands to 22.8
Base Case
$73.38
(+91%)
Market implied 100.0%, PE stable at 20.7
Bear Case
$24.95
(-35%)
Severe decline -20.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.1 to 8.1
Stabilization Target:
$38.61
(+0.3%)
PE Expansion Potential:
+0.3%
Share & Embed Analysis
Last updated: July 13, 2026 6:47 AM ET
Data refreshes hourly during market hours. Next update: 7:47 AM
Data refreshes hourly during market hours. Next update: 7:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 66 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 64 BUY |
